WU-CART-007 is under clinical development by Wugen and currently in Phase I for Relapsed Acute Myeloid Leukemia. According to GlobalData, Phase I drugs for Relapsed Acute Myeloid Leukemia have a 70% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how WU-CART-007’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

WU-CART-007 overview

WU-CART-007 is under development for the treatment of recurrent and refractory T-cell acute lymphocytic leukemia and lymphoblastic lymphoma (LBL), relapsed or refractory acute myeloblastic leukemia, permissible T-cell NHL subtypes will include: angioimmunoblastic T-cell lymphoma (AITL), enteropathy-associated T-cell lymphoma (EATL), monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL), peripheral T-cell lymphoma (PTCL) NOS, anaplastic large cell lymphoma (ALCL), adult T-cell leukemia/lymphoma T-cell prolymphocytic leukemia (T-PLL), extranodal NK/T cell lymphoma, transformed mycosis fungoides/Sezary Syndrome,  primary cutaneous gamma/delta T-cell lymphoma and hepatosplenic T cell lymphoma. The therapy constitutes of genetically manipulated universal allogeneic T cells which express a chimeric antigen receptor that is transduced by lentivirus. It targets cells expressing T cell antigen CD7 and is developed based on off-the-shelf fratricide-resistant CAR-T platform. It was also under development for the treatment of non-Hodgkin lymphoma.. It is administered through intravenous and parenteral route.

Wugen overview

Wugen is a biotechnology company that develops cell therapies for the treatment of hematologic cancer and other solid tumors. The company is investigating its lead product candidate WU-NK-101, an allogeneic off-the-shelf NK cell therapy for the treatment of acute myeloid leukemia (AML); and monoclonal antibodies (mAb) to treat other solid tumors. It is also developing an off-the-shelf fratricide-resistant CAR T cell therapy candidate, WU-CART-007 for treating T-cell acute lymphoblastic leukemia (T-ALL) and lymphoblastic lymphoma (LBL); and WU-NK-201, a memory NK cell therapy for the treatment of solid tumors. The company was funded by Aisling Capital, RiverVest Ventures, Velosity Capital Management, LYZZ Capital, BioGenerator, and others. Wugen is headquartered in St. Louis, Missouri, the US.

For a complete picture of WU-CART-007’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 7 February 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.